Patent ID: 9358213
Filing Date: 2016-06-07
CPC Classification: A61K,A61P

Claim Text:
1. A solid pharmaceutical composition for oral administration comprising duloxetine resin conjugate, wherein the duloxetine resin conjugate comprising 1% to about 40% by weight of duloxetine or a salt thereof conjugated to ion exchange resin particles to reduce degradation of the duloxetine or pharmaceutically acceptable in acidic pH upon oral administration of the pharmaceutical composition optionally with other pharmaceutically acceptable excipients; wherein the conjugated duloxetine resin particles are coated with pharmaceutically acceptable seal coat polymers followed by enteric coating polymers; wherein the pharmaceutically acceptable enteric polymer comprises one or more of shellac, methacrylic acid copolymer type C NF, cellulose butyrate phthalate, cellulose hydrogen phthalate, cellulose propionate phthalate, hydroxypropyl methylcellulose acetate, dioxypropyl methylcellulose succinate, carboxymethyl ethylcellulose and acrylic acid polymers/copolymers.